Ranibizumab and the Risk of Arterial Thromboembolic Events

NCT01319188 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

380

Enrollment

OTHER

Sponsor class

Stopped The study was terminated under the political pressure of the Federal Security Service of the Russian Federation (FSB) and the Russian Society of Cardiology

Conditions

Age-related Macular Degeneration
Coronary Artery Disease
Cerebrovascular Disorders

Interventions

DRUG: 0.5 mg of ranibizumab
PROCEDURE: 0.5 mg of ranibizumab + photodynamic therapy
OTHER: Sham injection

Sponsor

Ural State Medical University

Collaborators

[object Object]
[object Object]